Clinical Evaluation of Bexagliflozin and Other SGLT2 Inhibitors for Type 2 Diabetes Management

Abstract

To assess the clinical effectiveness and safety of Bexagliflozin and Cagglitazone (Cagelin) in the management of type 2 diabetes, we conducted a study involving three hundred type 2 diabetes patients admitted to the hospital from May 2022 to May 2023. The patients were randomly allocated into two study groups. The Bexagliflozin treatment group consisted of 150 patients, while the control group included 150 patients who were administered Cagelin. During a 4-month intervention period, both cohorts were subjected to a rigorous evaluation. We conducted a comprehensive analysis encompassing their demographic data, glycemic fluctuations, pre- and post-treatment body weight variations, as well as vigilantly monitored for any potential adverse events. The results indicate a significant decrease in FPG, 2HPG, HbA1c, and body weight indicators in both groups after drug treatment. Notably, the Bexagliflozin group demonstrated a significantly greater reduction in blood glucose and body weight indices compared to the control group. The incidence of severe adverse reactions was slightly higher in the Bexagliflozin group at 7.33% compared to 6.67% in the control group, but this difference was not statistically significant (P>0.05). When compared to other SGLT2 inhibitors, Bexagliflozin demonstrates a more pronounced effect in regulating blood sugar levels and inhibiting weight gain in the treatment of type 2 diabetes.